News

Retatrutide Pediatric Compounding Restrictions: FDA Pediatric Advisory Committee Review After GLP-1 Pediatric Prescription Surge
FDA's Pediatric Advisory Committee reviews retatrutide compounding for children after GLP-1 prescriptions surge. What parents and clinicians must know Read more...
Retatrutide and AOD-9604 Compounding Oversight: State Pharmacy Boards Step In After FDA Guidance Leaves Gaps
State pharmacy boards are moving faster than the FDA to restrict compounded retatrutide and AOD-9604. Learn what this means for access, safety, and Read more...
Retatrutide Compounding Restrictions in 2026: FDA GLP-1 Quality Guidance Reshapes Access
FDA's 2026 guidance on GLP-1 quality standards forces compounding pharmacies to meet USP and peptide-specific testing for retatrutide and AOD-9604 Read more...
Retatrutide Compounding Pharmacy Restrictions: FDA Inspection Findings Reshape Access
FDA inspection findings on retatrutide compounding pharmacies reveal sterility and sourcing failures. These restrictions could reshape access to the Read more...
Retatrutide Regulatory Update: FDA Response to GLP-1 Oral Pill Approval and Compounding Pharmacy Implications
FDA has not formally banned retatrutide compounding, but warning letters, a panel vote on AOD-9604, and oral GLP-1 approval are narrowing the legal Read more...
FDA Panel Vote on Six Peptides: How AOD-9604 and Retatrutide Regulatory Paths Diverge Under New Scrutiny
FDA panel vote on six peptides reveals divergent regulatory paths for AOD-9604 and retatrutide under 503A/503B compounding rules. Read more...
Retatrutide vs AOD-9604: UK Pill Approval Shifts Regulatory Path
The UK's approval of a new weight-loss pill reshapes the regulatory outlook for peptides like retatrutide and AOD-9604. Compounding pharmacies face Read more...
AOD-9604 and FDA’s Peptide Panel Vote: Will Fragment 177-191 Face New Scrutiny?
The FDA's peptide panel vote didn't name AOD-9604, but the fragment 177-191 approach now faces new scrutiny. Compounding pharmacies may lose Read more...
FDA Panel Votes on Six Peptides: Could Retatrutide’s Regulatory Path Be Affected?
FDA advisory panel votes on six peptides, including retatrutide and AOD-9604, signaling tighter compounding rules. The split decision on AOD-9604 and Read more...
Retatrutide Compounding Risks Amid FDA GLP-1 Quality Concerns
FDA warning letters on retatrutide compounding highlight sterility failures and misbranding. Learn what the crackdown means for research peptide users Read more...
Retatrutide Compounding Crackdown: FDA Warning Letters Signal Shift After GLP-1 Quality Concerns
FDA warning letters to compounding pharmacies signal a crackdown on retatrutide and AOD-9604 after GLP-1 quality failures. The enforcement shift Read more...
Retatrutide Compounding Under Fire After GLP-1 Quality Study
A MedPage Today investigation into compounded GLP-1 quality raises safety flags for retatrutide users. Learn what the findings mean for pharmacy Read more...
Retatrutide Trial Data: Regulatory Implications for Compounding Pharmacies
Retatrutide's Phase 2 trial data showing 24% weight loss raises urgent regulatory questions for compounding pharmacies. This analysis examines FDA Read more...